Patent expiry and costs for anti-cancer medicines for clinical use : expiry and costs anti-cancer medicines by Godman, Brian et al.
Godman, Brian and Wild, Claudia and Haycox, Alan (2017) Patent expiry 
and costs for anti-cancer medicines for clinical use : expiry and costs 
anti-cancer medicines. Generics and Biosimilars Initiative journal. pp. 1-
3. ISSN 2033-6403 (In Press) , 
This version is available at http://strathprints.strath.ac.uk/60241/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (http://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (http://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
1 
 
Patent expiry and costs for anti-cancer medicines for clinical use 
 
(Commentary on Venkatesan et al ± Accepted for Publication GaBI Journal. Please keep 
CONFIDENTIAL) 
 
*Godman B, BSc, PhD1,2,3, Wild C4, PhD, Haycox A3 PhD 
 
1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, 
United Kingdom. Email: Brian.godman@strath.ac.uk 
2Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, 
Karolinska University Hospital Huddinge, Stockholm, Sweden. Email: Brian.Godman@ki.se 
3Health Economics Centre, University of Liverpool Management School, Liverpool, UK. Email: 
a.r.haycox@liverpool.ac.uk  
4Ludwig Boltzmann Institute of Health Technology Assessment, Vienna, Austria. Email: 
Claudia.Wild@hta.lbg.ac.at 
 
*Author for correspondence: Strathclyde Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow G4 0RE, United Kingdom. Email:  Brian.godman@strath.ac.uk. Telephone: 
0141 548 3825. Fax: 0141 552 2562 and Division of Clinical Pharmacology, Karolinska Institute, 
Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden. Email: 
Brian.Godman@ki.se. Telephone + 46 8 58581068. Fax + 46 8 59581070 
Drs Brian Godman, Claudia Wild and Alan Haycox review the paper by Venkatesan et al on the 
patent expiry of (non-) tyrosine kinase inhibitors. 
 
Venkatesan et al are to be congratulated on publishing their interesting paper providing general 
insight into exclusivity and patent rights for the (non-) tyrosine kinase inhibitors (TKIs) (1) used in the 
treatment of patients with cancer. The authors point out that the TKIs and some of the non-TKIs have 
long exclusive rights, which is a concern especially given some of their marginal or small health gains 
versus current standards. However, it is not clear why the patent lives are so long, and why there are 
such differences between Europe and the US. This may well be because of orphan status and other 
considerations; however, this information is not provided in their paper. The authors suggest that the 
long patent life may be due to the limited development time for these compounds; however, this may 
also not necessarily be the case. In any event, as Venkatesan et al point out (1), there is increasing 
concern with the growing cost of new medicines (2), which would be enhanced by granting premium 
prices and long patent lives for new medicines. Countries, even high income countries, are now 
struggling to fund all new valued medicines, which is not in the interest of any key stakeholder group 
(2, 3).  
 
It is not clear why the TKIs were singled out for special attention in this paper. In addition, the review 
suggests that all TKIs are equally beneficial, which is not the case. However, imatinib is a concern to 
payers with sales enhanced by off-label use with initially high prices granted on the basis of orphan 
status (4). Global sales were estimated at US$4.75 billion in 2014, making imatinib the fourteenth 
highest selling product worldwide that year (5). The rationale for choosing the non-TKIs is also not 
explained. Never-the-less the paper gives very good insights into their likely generic availability, which 
is crucial for health authorities given the low prices that could be achieved for some of these cancer 
medicines (6). 
 
In the discussion, the authors make a number of good points regarding high prices for new cancer 
medicines. This is a key concern across countries, with prices of new cancer medicines rising up to 
ten fold during the past decade (7, 8). Prices for new cancer medicine now average US$150,000 or 
more per year of life gained (9), often with marginal health gain versus current standards (10).  In their 
recent review, Grössmann and Wild (11) documented that out of 134 new indications approved for 
cancer medicines since 2009, no data was available for progression free survival or overall survival in 
27%. A positive impact was seen for median overall survival in 55.5%; however only 16% showed a 
difference of more than 3 months (11), which is increasingly seen as a minimum for a new cancer 
medicine to be seen as an advance (2, 10). These concerns with ever increasing prices led to calls by 
US oncologists to pharmaceutical companies to moderate their growth in the future (12, 13). High 
prices are also a major concern to lower and middle income countries, which currently account for 
more than 70% of cancer mortality (14). Increasing prices of new cancer medicines is also threatening 
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the sustainability of universal health care in those countries that provide this given ever growing 
prevalence rates for cancer (7, 15). This is leading to calls that cancer should no longer be singled out 
for special attention as this has been exploited (16).  
 
It is estimated by some authors that the cost of bringing a new cancer medicine to the market is lower 
than US$100million (13), and that prices of generic bortezomib, dasatinib, everolimus and gefitinib 
could potentially be as low as 1% of the current selling price (6). This justifies calls for price 
moderation for new cancer medicines, as well as initiatives to make generics of valued cancer 
medicines available as early as possible with the cost of cancer medicines now accounting for an ever 
increasing proportion of the total costs of cancer care (7). In the meantime, health authorities need to 
critically re-think how new cancer medicines should be valued, especially given concerns with 
surrogate markers (2, 10, 17). Payers and providers also need to increasingly collaborate before 
product launch to agree likely patient populations where new cancer medicines will be most valued to 
limit their budget impact (18), and keep to this, as well as seek extensive discounts through risk 
sharing arrangements (2, 19). 
 
Overall, the paper by  paper Venkatesan et al gives good insights into likely generic availability of key 
cancer medicines, which is crucial for health authorities given the potentially low prices that could be 
achieved (6). The authors are to be congratulated on this. The paper also highlights the need for 
increased transparency in relation to development and patent times, the need for new cancer 
medicines to be considered similarly to all other medicines for pricing and reimbursement 
considerations, and not singled out for special status, as well as greater transparency in pricing 
considerations. The latter given increasing concerns with high prices for new cancer medicines 
coupled with the low cost of goods of some (6, 13). Finally, the observation that the development time 
for these (non-) TKIs is rather short should be investigated further through researching the actual 
timescales for Phases I to III and earlier of the TKIs. 
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